Syndax Pharmaceuticals, Inc., a Waltham, MA-based clinical-stage epigenetics oncology company, has issued $6m in convertible notes and warrants to its Series A investors.
All existing investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences participated in the securities offering.
This issue brings the total investment to date to $55m.
The funding will be used to complete a randomized Phase 2 study of entinostat, a class I isoform selective HDACi in advanced and metastatic breast cancer.
Formed in 2005, the company’s intellectual property is based on work from scientific founder Ronald Evans, PhD, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.